Evidence-Based Decision-Making Guide to Genetic Testing for Infertility: Essential Tests and the Clear Boundary of Overtreatment

After receiving routine semen analysis and sex hormone reports, many couples are advised to "undergo genetic testing"—ranging from single-item tests costing a few hundred yuan to comprehensive "full genetic panels" priced in the tens of thousands, with numerous test options and exaggerated promotional claims. Most patients face a genuine dilemma: they fear missing critical underlying causes if they skip testing, yet worry about wasting money on reports that only fuel anxiety if they proceed.

This guide synthesizes guidelines from authoritative societies including ESHRE, ASRM, ACMG, and EAU, combined with data from multiple peer-reviewed studies, to help you establish a judgment framework that can be directly applied. The core principle of the entire text is as follows:The only criterion for determining whether a genetic test is worth conducting is whether its results can change the subsequent treatment plan.Tests that cannot guide action are wasteful, no matter how cheap; tests that help avoid detours are cost-effective, no matter how expensive.

First, establish the core judgment scale: the three-tier classification method for "Decision-Making Change Potential"

The value of genetic testing has never been proportional to the number of genes tested, but is directly related to how many evidence-supported action branches a positive result can lead to. We categorize all tests into three tiers, from highest to lowest clinical value:

• Layer 1: Essential Needs DetectionPositive results directly change the treatment pathway, supported by clear guideline recommendations and evidence-based medicine;

• Layer 2: Optional Detection: May provide an explanation of the etiology, but rarely changes the current treatment plan; expectations must be weighed carefully.

• Level 3: Lightning Protection InspectionInsufficient evidence or minimal clinical utility, representing typical overtreatment.

A Y-chromosome microdeletion test for men with azoospermia has far greater clinical value than a comprehensive infertility panel covering 700 genes: the former’s positive results directly determine sperm retrieval strategies, whereas most positive findings from the latter are variants of uncertain significance that serve only to increase anxiety without providing practical benefits.

Tier 1: Essential Needs Assessment – Match to Clinical Scenarios

This is a core recommendation consistently strongly endorsed by both domestic and international reproductive guidelines, with results that directly determine subsequent treatment directions and are undisputed. Each scenario begins with a one-sentence conclusion for quick reference.

Scenario 1: Male non-obstructive azoospermia or severe oligozoospermia (sperm concentration <5 million/mL)

Bottom line: You must undergo karyotyping and Y-chromosome AZF microdeletion testing, as the results of these two tests directly determine whether sperm retrieval surgery is necessary.

Evidence-Based Data:

• Among all infertile men, the detection rate of karyotype abnormalities is approximately 6%; inNon-obstructive azoospermiaAmong the population, chromosomal abnormalities and Y-chromosome microdeletions together account for approximately 25%, with Klinefelter syndrome (47,XXY) being the most common, representing 27% of karyotype abnormalities.

• The overall detection rate of Y chromosome microdeletions in men with non-obstructive azoospermia or oligospermia is approximately 8.5%, specifically 9.2% in cases of azoospermia and 7.1% in cases of oligospermia, with deletions in the AZFc region being the most common.

Direct treatment pathway:

• Diagnosis of Klinefelter Syndrome: No Need for Blind Use of "Sperm-Producing Medications"; Direct Assessment Is RecommendedMicrosurgical sperm retrievalor sperm donation protocol;

• Complete deletion of the AZFa/AZFb regions: The success rate of testicular sperm extraction is extremely low; surgery can be skipped directly to avoid physical trauma and financial loss.

• AZFc deletion: Approximately 50% chance of sperm retrieval; micro-TESE can be attempted.

Supplementary note: CFTR gene testing is required only when obstructive azoospermia is confirmed and physical examination suggests congenital bilateral absence of the vas deferens (CBAVD); no additional testing is needed for routine oligoasthenozoospermia.

Scenario 2: Female premature ovarian insufficiency (POI) / primary amenorrhea / ovarian failure before age 40

Bottom line: Chromosomal karyotyping and FMR1 premutation testing are essential, as they clarify the etiology and guide reproductive planning.

Evidence-based data: Two tests can explain approximately 15%–20% of the etiology of idiopathic premature ovarian insufficiency (POI); FMR1 premutation carriers have a 5.41-fold increased risk of POI compared to the general population; the prevalence of POI in the overall population is approximately 3.5%.

Direct treatment pathway:

• Karyotyping to screen for sex chromosome abnormalities such as Turner syndrome not only helps explain the cause of premature ovarian failure but also guides long-term health management, including cardiovascular and skeletal care;

• Positive FMR1 directly indicates:Fertility PreservationThe fertility window may be narrower than expected, requiring early planning for egg freezing or family timing; at the same time, the risk of offspring developing Fragile X syndrome must be assessed.

Rational context: Large population studies indicate that only approximately 6.9% of FMR1 premutation carriers develop clinically defined primary ovarian insufficiency (POI). The value of testing lies in prompting more proactive reproductive decision-making, rather than providing a definitive timeline for menopause.

Scenario 3: Recurrent spontaneous abortion (≥2 first-trimester spontaneous abortions)

One-sentence conclusion: Both partners must undergo karyotype analysis; an abnormal result does not necessarily mean IVF is the only option, as the cumulative live birth rate is not significantly different from that of individuals with normal karyotypes.

Evidence-Based Data:

• Recurrent miscarriageIn couples, the detection rate of chromosomal abnormalities (primarily balanced translocations and inversions) is approximately 3%–5%;

• Balanced translocation carriers have a lower live birth rate in their first pregnancy (52.9% vs 72.4%), but the cumulative live birth rate reaches 81.4%, showing no statistically significant difference compared to non-carriers; a single-center cohort study showed that the proportion of healthy newborns was nearly identical between carriers and non-carriers (72.7% vs 71.2%).

Direct treatment pathway:

• Once chromosomal structural abnormalities are clearly identified, you can independently opt for third-generation IVF (PGT- SR) or natural conception under early monitoring, avoiding meaningless blind pregnancy preservation;

• Inversion has no significant impact on the live birth rate, and it does not warrant directly proceeding with IVF.

Optional supplement: If fresh products of conception are available, chromosomal microarray analysis (CMA) can be performed. CMA has higher resolution than traditional karyotyping and helps distinguish between random embryonic abnormalities and inherited genetic issues in the couple.

Scenario 4: Routine Preconception/Pre-Pregnancy Checkup

One-sentence conclusion: OptionalExtended carrier screeningIt checks for the risk of hereditary diseases in offspring and has nothing to do with "whether you can conceive."

Important clarification: This is a screening for the risk of autosomal recessive hereditary diseases in offspring, not an "infertility cause test." Do not confuse the concepts by bundling it into an "infertility package."

Evidence-Based Data:

• Among healthy individuals with no family history, 27.49% carry at least one of 11 recessive genetic disorders; when expanded to 220 diseases, the carrier rate reaches 62.3%; approximately 2–2.4% of couples are both carriers of pathogenic variants in the same gene, posing a risk of disease in their offspring.

• Health economics research has confirmed that preconception carrier screening is cost-effective in the long term and can significantly reduce the lifelong medical burden associated with birth defects.

A critical limitation (easily overlooked): Panel detection rates vary significantly across ethnic groups. For example, in cystic fibrosis (CFTR), the detection rate is 84%–90% among European whites but only 25%–69% among Asian populations; a negative result does not imply zero risk. The number of variants covered by the panel is more important than the laboratory brand.

Layer 2 · Optional Check: You may find an "explanation," but you cannot necessarily change the "solution."

This layer of testing primarily provides a molecular-level explanation of the underlying cause, rather than altering the current treatment pathway. It is suitable for individuals with specific phenotypes who can accept the expectation that it will likely not change their management plan.

Targeted Gene Panel / Whole Exome Sequencing (WES)

Recommended only in cases with clear specific clinical phenotypes, such as hypogonadotropic hypogonadism, recurrent oocyte maturation failure, disorders of sex development, or familial clustering of infertility.

True clinical value: It primarily provides an explanation of the etiology, aids in prognosis assessment, and guides genetic counseling for families. Real-world studies show that, among the general infertile population without specific phenotypes, whole-exome sequencing leads to clear adjustments in assisted reproductive treatment plans for only a small proportion of patients; for the vast majority, the results do not alter conventional ovarian stimulation or embryo transfer strategies.

The biggest pitfall—Variants of Uncertain Significance (VUS): The more genes covered by a large panel, the higher the probability of encountering VUS. These variants cannot be confirmed as disease-related nor completely ruled out; in most cases, they do not alter treatment and only increase anxiety. Before testing, be sure to ask: What are the principles for handling VUS?

Observations of Gender Differences in Clinical Testing

In clinical practice, the proportion of female infertility patients undergoing broad-spectrum genetic testing is significantly higher than that of male patients. Genetic testing in males is strictly driven by semen analysis parameters, with clear indications and standardized test panels; whereas in female infertility, cases labeled as "unexplained infertility,"Recurrent implantation failureVague indications are more common, and a higher proportion of non-essential large-panel tests are ordered.

If you are a woman with unexplained infertility and are recommended an extensive panel of tests, be sure to ask: How exactly will a positive result change your treatment plan? If the answer is vague, the value of this testing is highly questionable.

Level 3: Clear Red Flags – These tests are typical examples of overmedicalization

The following projects either lack sufficient evidence-based support or have extremely low clinical utility, representing the most prevalent areas of overtreatment in current infertility care.

1. MTHFR Gene Polymorphism TestingACMG has explicitly stated that this test has "very low clinical utility and should not be part of the routine evaluation for thrombophilia," and does not recommend it for the routine workup of recurrent pregnancy loss. The MTHFR C677T polymorphism is not causally linked to recurrent pregnancy loss, and there is no need to adjust folic acid supplementation dosage based on genotype; standard daily folic acid supplementation is sufficient.

2. Comprehensive Panel for Common Hereditary ThrombophiliaIt has evaluative value only in cases with a clear history of thrombosis or family history; in the general population with infertility or recurrent pregnancy loss, evidence linking these factors is weak, and positive results do not directly indicate a need for heparin therapy. Although meta-analyses have shown weak associations between certain coagulation factors and miscarriage, the studies exhibit high heterogeneity, and most have not controlled for confounding factors.

3. Various "spermatogenesis gene panels" and "ovarian reserve susceptibility gene tests". Most are based on scattered GWAS loci, offering only statistical associations without clear diagnostic value for etiology and no impact on treatment plans; in essence, they package anxiety under the guise of "comprehensiveness."

4. PGT-P (Preimplantation Genetic Testing for Polygenic Disorders)The formal ethical opinion issued by ASRM in 2026 explicitly states that PGT-P is "immature, unproven, and should not be used clinically"; the UK's HFEA has confirmed that it is illegal in the United Kingdom. Core issue: Complex diseases such as diabetes and hypertension are heavily influenced by environmental factors and lifestyle, with polygenic scores explaining only a very small fraction of the risk. Accuracy flaws: Different testing methods show low consistency in ranking risks for the same batch of embryos, failing to provide reliable predictive value. Important distinction: PGT-P ≠ conventional third-generation IVF. PGT-M (for monogenic disorders) and PGT-SR (for chromosomal structural rearrangements), which are components of conventional third-generation IVF, have clear clinical value; do not dismiss all third-generation IVF technologies due to the controversy surrounding PGT-P.

Avoiding Pitfalls: The 3 Most Common Genetic Testing Marketing Scams

1. Large bundle packages: core items + filler items, with prices multiplied several times

Typical script: "Just go ahead and do the full package—get everything checked thoroughly in one go, so you don’t have to come back later for additional tests."

Unpacking the tactic: Bundling 2–3 core tests recommended by guidelines, such as karyotyping and AZF analysis, with dozens of susceptibility genes lacking sufficient evidence, into a "full package"Infertility Genetic TestingCore items have fixed costs and clear value, while filler items have extremely low marginal costs yet can double the selling price.

Response: Require project unbundling, perform only the targeted tests recommended by guidelines, and reject bundled sales.

2. Confusing correlation with causation: Exploiting "genetic abnormalities" to sell anxiety and wellness treatments

Typical sales pitch: "Your gene has a mutation, which is the reason for your miscarriage or inability to conceive. You need to undergo genetic regulation first."

Deconstructing the scheme: It swaps "possible correlation" in academic research for "causation," using genetic test results to sell supplements and treatment plans for profit.

Response: As long as the intervention plan corresponding to the test results is "regimen adjustment" or "supplements," rather than a clear change in the treatment pathway, it is essentially over-testing.

3. Sequencing omnipotence: pushing whole-exome sequencing from the start

Typical sales pitch: "Whole-exome sequencing is the most comprehensive; it can identify the cause of the disease in a single test."

Tactic breakdown: Ignoring the fact that the positive rate is extremely low among the general infertile population and that variants of uncertain significance (VUS) are rampant, they use "comprehensive" to create a sense of security and charge high testing fees.

Approach: Use targeted testing to address solvable issues instead of performing whole-genome sequencing; do not recommend voluntary whole-exome sequencing for individuals with unexplained infertility and no specific phenotypes.

Clinical Decision Tool: Ask These 5 Questions Before Paying for Tests

You don’t need to memorize all gene names and guidelines—just bring these 5 questions to your appointment, and you can avoid 90% of the pitfalls.

1. If the test comes back positive, how exactly will our treatment plan change? Will we switch to a different sperm selection method or proceed with third-generation IVF (PGT)? If the answer is only “to help understand the cause,” without specifying concrete decision pathways, its clinical utility is likely insufficient.

2. Given my specific circumstances (sperm count/AMH value/number of miscarriages), what is the approximate positive detection rate of this test? Which guidelines recommend it? All standard mandatory items can be justified by ASRM, ESHRE, and Chinese Medical Association guidelines, with clear population-specific detection rate data.

3. If a report identifies variants of uncertain significance, what are your principles for handling them? Will this alter the treatment plan? Clarify the decision-making logic in advance to avoid being swayed by unfamiliar gene names and unnecessarily increasing anxiety.

4. Is this test recommended for my specific condition, or is it simply part of a bundled package? Match the tests to your clinical phenotype, not to an institution’s service menu.

5. For carrier screening, what is the detection rate of this panel in Chinese populations? How many pathogenic variants does it cover? Given that the spectrum of pathogenic variants varies significantly across different ethnic groups, a negative result indicates "reduced residual risk" rather than "zero risk."

Quick Reference: Decision Comparison Table

Final Words

In infertility treatment, the most expensive cost has never been testing fees, but rather the time spent on wrong paths and emotional burnout. Genetic testing is essentially a tool, not an answer. Choosing the right tool can help you avoid detours of six months or even years; choosing the wrong one merely buys you a pile of incomprehensible letters and numbers, adding to your anxiety.

Please remember two final principles:

1. Genetic testing is always phenotype-driven, not "the more comprehensive, the better."

2. All genetic test results must be interpreted in conjunction with professional genetic counseling. Do not search online to interpret the reports yourself, and never give up on treatment based solely on a single test report.